Published in Clin Gastroenterol Hepatol on October 15, 2010
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther (2014) 2.11
Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.03
Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci (2012) 0.92
The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. Clin Gastroenterol Hepatol (2014) 0.88
Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review. Dig Dis Sci (2014) 0.86
TNF signals via neuronal-type nitric oxide synthase and reactive oxygen species to depress specific force of skeletal muscle. J Appl Physiol (1985) (2013) 0.86
A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol (2012) 0.85
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol (2013) 0.85
Biological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: a US Medicare cohort study. BMJ Open (2015) 0.83
Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc (2011) 0.82
Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.80
Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Exp Gastroenterol (2011) 0.80
Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol (2011) 0.78
What is the impact of age on adult patients with inflammatory bowel disease? Clujul Med (2013) 0.77
[Safety of antirheumatic drug treatment in the elderly]. Z Rheumatol (2014) 0.77
Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol (2016) 0.76
Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther (2016) 0.76
Healthcare maintenance in elderly patients with inflammatory bowel disease. Ann Gastroenterol (2017) 0.75
Inflammatory Bowel Disease is Similar in Patients with Older Onset and Younger Onset. Inflamm Bowel Dis (2017) 0.75
Select a suitable treatment strategy for Crohn's disease: step-up or top-down. EXCLI J (2014) 0.75
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. Adv Ther (2017) 0.75
Age Disparities in the Use of Steroid-sparing Therapy for Inflammatory Bowel Disease. Inflamm Bowel Dis (2016) 0.75
Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol (2016) 0.75
Biologic therapy and surgery for crohn disease. Clin Colon Rectal Surg (2013) 0.75
Can elderly people be treated safely with anti-TNF agents? Inflamm Bowel Dis (2011) 0.75
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther (2016) 0.75
Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials. Eur J Clin Pharmacol (2013) 0.75
Elderly-Onset and Adult-Onset Ulcerative Colitis Are More Similar than Previously Reported in a Nationwide Cohort. Dig Dis Sci (2017) 0.75
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature (2007) 7.17
Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med (2011) 6.76
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology (2002) 5.71
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology (2002) 4.20
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet (2008) 3.36
Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology (2012) 3.35
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet (2009) 3.19
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis (2013) 3.01
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol (2005) 2.90
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc (2007) 2.62
Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol (2010) 2.60
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
Tolerogenic dendritic cells: cytokine modulation comes of age. Blood (2006) 2.51
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.36
Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A (2009) 2.31
Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes (2006) 2.29
Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology (2011) 2.21
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med (2011) 2.19
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis (2014) 2.17
Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol (2009) 2.17
Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol (2007) 2.14
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med (2014) 2.04
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis (2013) 2.03
An inter- and intra-laboratory comparison of breath ¹³CO₂analysis. Aliment Pharmacol Ther (2003) 2.03
Randomized controlled trial of botulinum toxin versus laparoscopic heller myotomy for esophageal achalasia. Ann Surg (2004) 1.98
Association of DLG5 R30Q variant with inflammatory bowel disease. Eur J Hum Genet (2005) 1.84
Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology (2013) 1.83
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr (2010) 1.82
Prevalence of celiac disease in inflammatory bowel diseases: An IG-IBD multicentre study. Dig Liver Dis (2009) 1.82
Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Hum Mol Genet (2010) 1.81
Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol (2009) 1.78
Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. Eur J Radiol (2007) 1.77
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Small bowel exploration by wireless capsule endoscopy: results from 314 procedures. Am J Med (2006) 1.66
Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol (2011) 1.65
Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease. Gastrointest Endosc (2003) 1.64
Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology (2008) 1.62
Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet (2012) 1.61
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60
Evidence-based appraisal of antireflux fundoplication. Ann Surg (2004) 1.59
Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet (2003) 1.57
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 1.55
A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet (2011) 1.54
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut (2011) 1.52
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's disease. J Crohns Colitis (2011) 1.52
Optical coherence tomography evaluation of ulcerative colitis: the patterns and the comparison with histology. Am J Gastroenterol (2006) 1.52
Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol (2003) 1.51
Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J Immunol (2007) 1.51
Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study. Dig Dis Sci (2012) 1.50
EUS diagnosis and simultaneous endoscopic retrograde cholangiography treatment of common bile duct stones by using an oblique-viewing echoendoscope. Gastrointest Endosc (2006) 1.49
A prospective, longitudinal study of nonconventional strictureplasty in Crohn's disease. J Am Coll Surg (2004) 1.49
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis. J Clin Gastroenterol (2003) 1.48
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol (2008) 1.47
Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm Bowel Dis (2007) 1.46
Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: is it useful in compensated cirrhosis? Dig Liver Dis (2012) 1.46
Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review. J Clin Gastroenterol (2014) 1.46
TNFα inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease. Gut (2011) 1.45
Prevalence and clinical associations of prolonged prothrombin time in adult untreated coeliac disease. Eur J Gastroenterol Hepatol (2004) 1.45
Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. J Clin Gastroenterol (2012) 1.44
Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis (2006) 1.44
"Appropriateness" or "prioritization" for GI endoscopic procedures? Gastrointest Endosc (2006) 1.43
Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. Intern Emerg Med (2011) 1.43
Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. J Gastrointest Surg (2013) 1.42
Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis (2011) 1.41
Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol (2005) 1.40
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease. J Crohns Colitis (2012) 1.40
Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial. Dig Liver Dis (2011) 1.40
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut (2013) 1.37